Having great support throughout treatment is important

Support can include:

  • your doctor
  • a loved one
  • online or in-person groups
  • tools and resources for your ARIKAYCE journey

Stay up to date with information about MAC lung disease and ARIKAYCE.

Whether you’re considering ARIKAYCE, about to begin treatment, or you’re already on ARIKAYCE, there are resources available throughout your journey. Find the right type of support by choosing a tab that best describes your needs.

    Savings and Financial Assistance

    • arikayce cost

      Insmed is committed to providing access to ARIKAYCE

    Insurance covers ARIKAYCE for most people. There are also savings and financial support resources available for eligible patients.

    You may be eligible for a co-pay as low as $0 for ARIKAYCE.*

    If you have commercial or private insurance, you may be able to save on out-of-pocket costs with the ARIKAYCE Co-pay Savings Program.

    Your Arikares Coordinator and specialty pharmacy can provide you with financial assistance information.

    Eligibility can be determined by calling the Arikares® Support Program at 1-833-ARIKARE (1-833-274-5273) or 1-973-437-2376.

    Not valid for prescriptions covered by or submitted for reimbursement under Medicaid, Medicare, Veterans Affairs (VA), Department of Defense (DoD), TRICARE or similar federal or state programs, including any state pharmaceutical assistance program.
    arikayce cost support

    For any questions about cost or insurance coverage, call 1-833-ARIKARE (1-833-274-5273) or 1-973-437-2376 Monday through Friday from 8 AM to 8 PM Eastern Time

    Co-pay Savings Program Terms and Conditions

    Patients who are eligible may pay as little as a $0 co-pay every month. Patient will be responsible for any co-pay amounts exceeding program limits. Depending on the private or commercial health insurance plan, savings may apply toward co-pay, coinsurance, or deductible. Keep in mind that co-payments, coinsurance, and deductibles are all different types of out-of-pocket costs and you may still have out-of-pocket costs even if you are eligible for this program. Refer to your insurance plan documents if you have questions related to your total out-of-pocket costs for ARIKAYCE.

    Who is eligible?

    Patients who have been prescribed ARIKAYCE, are at least 18 years of age, a resident of the 50 United States, the District of Columbia, or Puerto Rico, and have commercial or private health insurance may be eligible for the ARIKAYCE Co-pay Savings Program. ARIKAYCE must be covered by your commercial or private insurance. This program is not valid for cash-paying customers. This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicaid, Medicare, VA, DoD, TRICARE or similar federal or state programs, including any state pharmaceutical assistance program.

    Patients who are currently ineligible for the ARIKAYCE Co-pay Savings Program may reapply if their circumstances change.

    This is not an insurance benefit, and does not cover or provide support for supplies, procedures, or any physician-related services associated with ARIKAYCE. General, non-product specific insurance deductibles are also not covered by this program. Insmed reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms and conditions at any time without notice. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this offer. This offer is not conditioned upon, or reward for, any past, present, or future purchase, including refills. The co-pay card is non-transferable, limited to one per person, and cannot be combined with any other offer or discount. This program is not valid where prohibited by law, taxed, or restricted. Offer has no cash value.

    For Patients: If your prescription is covered by insurance, you may need to notify the insurance carrier of redemption of this co-pay card. By redeeming this co-pay card, you are certifying that (1) you are not a beneficiary of any government-funded program as previously noted; (2) should you begin receiving prescription benefits from any government-funded program, you will withdraw from this program; and (3) you understand that adherence to the terms and conditions of this offer is necessary to ensure compliance with laws pertaining to any government-funded program. For questions regarding your eligibility or benefits or if you wish to discontinue your participation, please call 1-833-ARIKARE (1-833-274-5273) or 1-973-437-2376.

    BY PARTICIPATING IN THE ARIKAYCE CO-PAY SAVINGS PROGRAM, YOU AND YOUR PHARMACIST UNDERSTAND AND AGREE TO COMPLY WITH THESE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.

Next: Make connections
download icon

IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING AND INDICATION ARIKAYCE is associated with: risk of increased respiratory adverse reactions including allergic inflammation of lungs, coughing up blood, severe breathing problems and worsening of COPD.

ARIKAYCE can cause serious side effects, including:

  • allergic inflammation of the lungs. These respiratory problems may be symptoms of allergic inflammation of the lungs and often come with fever, wheezing, coughing, shortness of breath, and fast breathing
  • coughing up of blood (hemoptysis). Coughing up blood is a serious and common side effect of ARIKAYCE
  • severe breathing problems. Severe breathing problems can be symptoms of bronchospasm. Bronchospasm is a serious and common side effect of ARIKAYCE. Bronchospasm symptoms include shortness of breath, difficult or labored breathing, wheezing, and coughing or chest tightness
  • worsening of chronic obstructive pulmonary disease (COPD). This is a serious and common side effect of ARIKAYCE
  • serious allergic reactions. Serious allergic reactions that may lead to death have happened to people who take ARIKAYCE. Stop taking ARIKAYCE right away and get emergency medical help if you have any of the following symptoms of a serious allergic reaction: hives, itching, redness or blushing of the skin (flushing), swollen lips, tongue or throat, trouble breathing or wheezing, shortness of breath, noisy high-pitched breathing (stridor), cough, nausea, vomiting, diarrhea, feel cramps in your stomach area, fast heart rate, feeling light headed, feeling faint, loss of control of the bowels or bladder (incontinence), and dizziness

While using ARIKAYCE, these side effects may become serious enough that treatment in a hospital is needed. Call your healthcare provider or get medical help right away if you have any of these serious side effects while taking ARIKAYCE. Your healthcare provider may ask you to stop using ARIKAYCE for a short period of time or completely stop using ARIKAYCE.

Do not use ARIKAYCE if you are allergic to any aminoglycoside, or any of the ingredients in ARIKAYCE.

Before using ARIKAYCE, tell your healthcare provider about all medical conditions, including if you:

  • have asthma, COPD, shortness of breath, or wheezing (bronchospasm)
  • have been told you have poor lung function
  • have hearing problems, such as ringing in your ears or hearing loss
  • have dizziness or a sense of the room spinning
  • have kidney problems
  • have neuromuscular disease, such as myasthenia gravis
  • are pregnant or plan to become pregnant. It is not known if ARIKAYCE can harm your unborn baby. ARIKAYCE is in a class of medicines that may be connected with complete deafness in babies at birth. The deafness affects both ears and cannot be changed
  • are breastfeeding or plan to breastfeed. It is not known if the medicine in ARIKAYCE passes into your breast milk and if it can harm your baby. Talk to your healthcare provider about the best way to feed your baby during treatment with ARIKAYCE

Tell your healthcare provider about all the medicines you take, including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements.

ARIKAYCE may cause serious side effects, including:

  • hearing loss or ringing in the ears (ototoxicity). Ototoxicity is a serious and common side effect of ARIKAYCE. Tell your healthcare provider right away if you have hearing loss or you hear noises in your ears, such as ringing or hissing. Tell your healthcare provider if you start having problems with balance or dizziness (vertigo)
  • worsening kidney problems (nephrotoxicity). ARIKAYCE is in a class of medicines which may cause worsening kidney problems. Your healthcare provider may do a blood test to check how well your kidneys are working during your treatment with ARIKAYCE
  • worsening muscle weakness (neuromuscular blockade). ARIKAYCE is in a class of medicines which can cause muscle weakness to get worse in people who already have problems with muscle weakness (myasthenia gravis)

The most common side effects of ARIKAYCE include: changes in voice and hoarseness (dysphonia), cough during or after a dose of ARIKAYCE, especially in the first month after starting treatment, muscle pain, sore throat, tiredness (fatigue), diarrhea, nausea, headache, fever, decreased weight, vomiting, rash, increased sputum, or chest discomfort.

These are not all of the possible side effects of ARIKAYCE. Call your doctor or pharmacist for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

What is ARIKAYCE?

ARIKAYCE is used in combination with multidrug therapy for adults who still test positive for MAC lung disease after at least 6 months on multidrug treatment alone.

ARIKAYCE was approved by FDA using the Limited Population pathway. This means FDA has approved this drug for a limited and specific patient population, and studies on the drug may have only answered focused questions about its safety and effectiveness.

ARIKAYCE was studied in adult patients. It is not known if ARIKAYCE is safe and effective in children younger than 18 years of age.